Core Viewpoint - The announcement from Kew Flower Pharmaceutical indicates the acceptance of the registration application for Fusidic Acid Cream by the National Medical Products Administration, which is a significant step towards market entry for this product [1] Group 1: Company Information - Kew Flower Pharmaceutical's wholly-owned subsidiary, Harbin Kew Flower Pharmaceutical Co., Ltd., has received the acceptance notice for the registration of Fusidic Acid Cream [1] - The primary indications for this medication include various skin infections such as pustules, boils, carbuncles, paronychia, wound infections, furuncles, sweat gland inflammation, erythema, folliculitis, and common acne [1] - The cream is suitable for use on facial and scalp infections without affecting appearance [1]

上述药品在获国家药品监督管理局注册上市许可申请受理后，将转入国家药 品监督管理局药品审评中心进行审评审批，鉴于药品审评周期长、环节多，期间 受不确定性因素影响，具体完成时间、审批结果存在不确定性。提醒广大投资者 审慎决策，注意投资风险。 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）全资子公司 哈尔滨葵花药业有限公司于近日收到国家药品监督管理局下发的关于夫西地酸 乳膏申请注册上市许可的《受理通知书》，现将有关情况公告如下： 一、 药物的基本情况 1、产品名称：夫西地酸乳膏 7、拟定适应症（或功能主治）：本品主治由葡萄球菌、链球菌、痤疮丙酸 杆菌、极小棒状杆菌及其他对夫西地酸敏感的细菌引起的皮肤感染。主要适应症 包括:脓疱、疖、痈、甲沟炎、创伤感染、须疮、汗腺炎、红癣、毛囊炎、寻常 性痤疮，本品适用于面部和头部等部位的感染而无碍外观。 二、风险提示 证券代码：002737 证券简称：葵花药业 公告编号：2025-072 葵花药业集团股份有限公司 关于夫西地酸乳膏申请注册上市许可获得受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特此公告。 ...

Core Points - Recently, Kew Flower Pharmaceutical announced that it received a warning letter from the Heilongjiang Regulatory Bureau of the China Securities Regulatory Commission and a regulatory letter from the Shenzhen Stock Exchange [1] - The regulatory letter mentioned that in 2024, Kew Flower Pharmaceutical conducted procurement business with Shanghai Haiwei Biotechnology Co., Ltd. for an amount of 32.3836 million yuan, which accounted for 0.68% of the company's most recent audited net assets [1] - Gele Rui (Wuxi) Nutrition Technology Co., Ltd. is an affiliated legal entity of the company, and Shanghai Haiwei is a wholly-owned subsidiary of Gele Rui [1] - The transaction constitutes a related party transaction, and Kew Flower Pharmaceutical failed to follow the required review procedures and information disclosure obligations [1] - The announcement pointed out that the chairman, general manager, and board secretary of Kew Flower Pharmaceutical did not fulfill their due diligence obligations and bear primary responsibility for the violations [1]

Core Points - The company received a warning letter from the Heilongjiang Securities Regulatory Bureau regarding violations of disclosure regulations related to a related party transaction [1][2] - The transaction involved a procurement deal with Shanghai Haiwei Biotechnology Co., a wholly-owned subsidiary of a related entity, totaling 32.38 million yuan, which is 0.68% of the company's latest audited net assets [1] - The company's chairman, general manager, and board secretary were found primarily responsible for failing to fulfill their diligence obligations [1] Summary by Sections - **Regulatory Action** - The Heilongjiang Securities Regulatory Bureau issued a warning letter to the company and its executives as an administrative regulatory measure [2] - The warning will be recorded in the securities and futures market integrity archives [2] - **Transaction Details** - The related party transaction involved a total amount of 32.38 million yuan [1] - This amount represents 0.68% of the company's most recent audited net assets [1] - **Responsibility** - The chairman, general manager, and board secretary of the company did not comply with the required diligence obligations, leading to their accountability for the violations [1]

Core Viewpoint - The company received a warning letter from the Heilongjiang Securities Regulatory Bureau for failing to comply with related party transaction disclosure regulations, involving a transaction amount of 32.38 million yuan, which is 0.68% of the company's latest audited net assets [1][2]. Group 1: Regulatory Actions - The Heilongjiang Securities Regulatory Bureau issued a warning letter to the company and its executives, including the chairman and general manager, for not following the required procedures for related party transactions and information disclosure [2]. - The warning letter will be recorded in the securities and futures market integrity archives [2]. Group 2: Related Party Transactions - The company engaged in a procurement transaction with Shanghai Haiwei Biotechnology Co., a wholly-owned subsidiary of its related party, Geluori (Wuxi) Nutrition Technology Co., with a transaction amount of 32.38 million yuan [1]. - The company did not fulfill the necessary review procedures and disclosure obligations for this related party transaction, violating multiple provisions of the Information Disclosure Management Measures for Listed Companies [1].

证券代码：002737 证券简称：葵花药业 公告编号：2025-070 葵花药业集团股份有限公司 关于公司及相关人员收到黑龙江证监局警示函的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 葵花药业集团股份有限公司（以下简称"公司"）于近日收到中国证券监督 管理委员会黑龙江监管局（以下简称"黑龙江证监局"）出具的《关于对葵花药 业集团股份有限公司、关玉秀、关一、周广阔采取出具警示函措施的决定》〔2025〕 48 号（以下简称"警示函"），现将相关内容公告如下： 一、警示函的具体内容 吸取教训，加强证券法律法规学习，切实提高公司内控管理及规范运作水平，及 时依法履行信息披露义务，并于收到行政监管措施决定30日内向我局提交书面报 告。 如果对本监督管理措施不服，可以在收到本决定书之日起60日内向中国证 券监督管理委员会提出行政复议申请，也可以在收到本决定书之日起6个月内向 有管辖权的人民法院提起诉讼。复议与诉讼期间，上述监督管理措施不停止执 行。 二、相关情况说明 公司及相关人员高度重视警示函所指出的问题，深刻反思，汲取教训，切实 加强对《公司法》、《证券法》 ...

证券代码：002737 证券简称：葵花药业 公告编号：2025-071 葵花药业集团股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 经葵花药业集团股份有限公司（以下简称"公司"）第五届董事会第六次会 议、第五届监事会第四次会议、公司 2024 年年度股东大会审议通过，公司决定 使用闲置自有资金额度不超过 20 亿元人民币进行现金管理，上述额度自股东大 会审议通过之日起 12 个月内有效，有效期内，上述额度可滚存使用。 授权董事长在上述期限和额度内，行使本次现金管理的决策权并签署相关法 律文件，由公司财务部门负责具体实施。 有关上述具体内容详见《上海证券报》、《证券日报》、巨潮资讯网 （http:www.cninfo.com.cn）公司公告。 二、投资风险及风险控制措施 1、投资风险 公司在进行现金管理过程中，会尽可能选择安全性高、流动性好的低风险品 种，但金融市场受宏观经济、政策、产品流动性等综合因素影响较大，存在因市 场波动、发行主体、流动性受限等原因导致现金管理本金受损、投资收益不达预 期的风险。 ...

Core Viewpoint - The company is committed to optimizing its business model and enhancing operational management to drive performance improvement [1] Group 1 - The company will continue to implement its research and development strategy of "buy, transform, connect, and research" [1] - The company aims to rationally allocate resources and steadily advance ongoing projects [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Harbin Kuaihua Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration regarding the application for the registration and marketing authorization of Clobetasol Propionate Ointment, which is intended for local treatment of mild to moderate atopic dermatitis in patients aged 3 months and older [1] Group 1 - The product is classified as a Class 4 chemical drug [1] - The drug review process is lengthy and involves multiple steps, leading to uncertainty regarding the completion time and approval results [1] - The company will actively promote the marketing authorization process for this product and will continue to monitor the approval status, ensuring timely information disclosure [1]

证券代码：002737 证券简称：葵花药业 公告编号：2025-069 葵花药业集团股份有限公司 关于克立硼罗软膏申请注册上市许可获得受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 7、拟定适应症（或功能主治）：本品适用于 3 月龄及以上轻度至中度特应 性皮炎患者的局部外用治疗。 二、风险提示 上述药品在获国家药品监督管理局注册上市许可申请受理后，将转入国家药 品监督管理局药品审评中心进行审评审批，鉴于药品审评周期长、环节多，期间 受不确定性因素影响，具体完成时间、审批结果存在不确定性。提醒广大投资者 审慎决策，注意投资风险。 1 2、剂型：软膏剂 3、受理号：CYHS2503831 4、申请事项：境内生产药品注册上市许可 5、申请人：哈尔滨葵花药业有限公司 公司将积极推进该产品的上市许可工作并持续关注审批情况，及时履行信息 披露义务。 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）全资子公司 哈尔滨葵花药业有限公司于近日收到国家药品监督管理局下发的关于克立硼罗 软膏申请注册上市许可的《受理通知书》，现将有关情况公告如下： 一、 药物的基 ...